This is HEBERSaVax, a therapeutic vaccine, or active immunotherapy, developed by the Center for Genetic Engineering and Biotechnology, which in Phase II clinical trials is showing few and tolerable adverse side effects.

These are elements that allow this candidate to be combined even with conventional therapies, without increasing toxicity, Yanelys Morera, the project leader and a full member of the Cuban Academy of Sciences, explained to the press.

The scientist explained that when a tumor grows, it is an actively growing mass that will need nutrients and oxygen. The product in question targets the ways in which the disease feeds, in addition to triggering cellular responses that halt tumor growth and thus benefit the patient.

We are looking at a candidate with multiple functions, as this product “produces specific antibodies” that cut off blood flow to the tumor, while simultaneously restoring the individual’s ability to attack the cancer with an immune response.

Reporting that the research has gone through several stages, the most recent being the Phase II clinical trials, where we have tried to target specific locations, she emphasized.

The project leader stressed that this type of therapy is very safe and can even be combined with conventional therapies without increasing toxicity.

Many patients who have received the candidate within the framework of the clinical trial have shown significant and positive effects on their quality of life. They have had complete responses, the scientist pointed out.

These results were presented to Cuban President Miguel Diaz-Canel at his regular meeting with Experts and Scientists on Health issues.

jdt/arm/mem/alb